AGTR2 and Alzheimer disease: Many innovative therapies are still in the experimental phase such as atomoxetine (selective norepinephrine reuptake inhibitor), losartan (angiotensin 2 receptor agonist), genistein (anti-inflammatory isoflavone neuroprotective agent), trans-resveratrol (polyphenol antioxidant plant estrogen), and drugs targeting AD-associated symptoms such as brexpiprazole (serotonin dopamine activity modulator) and suvorexant (orexin receptor antagonist), with more investigation and clinical research studies required for full approval.